BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced it will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET. Interested parties can access live and archived webcasts via the investors section of the company's website at ir.biostemtechnologies.com.
This event provides a platform for BioStem to showcase its proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—which are designed to preserve the natural properties of perinatal tissues for clinical use. The company's allografts are utilized across various medical specialties, and its portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™. With an expanding product lineup and a national commercial footprint, BioStem is positioned to advance regenerative medicine.
The presentation at a prominent healthcare conference like Needham's underscores the growing interest in regenerative therapies and BioStem's role in the sector. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). This accreditation highlights BioStem's commitment to rigorous standards, which is critical for clinician adoption and patient safety.
Investor and analyst attention at the conference could influence BioStem's market visibility and potentially impact its stock performance. The company's focus on innovation and quality, combined with its public listing, makes this presentation a key opportunity to communicate its value proposition to the investment community. For more details, visit biostemtechnologies.com or follow the company on X and LinkedIn.
